SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)
Authors
Keywords
-
Journal
Clinical & Translational Oncology
Volume 22, Issue 2, Pages 193-200
Publisher
Springer Science and Business Media LLC
Online
2019-12-30
DOI
10.1007/s12094-019-02262-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Germline-Focused Analysis of Tumour-Only Sequencing: Recommendations from the ESMO Precision Medicine Working Group
- (2019) D Mandelker et al. ANNALS OF ONCOLOGY
- Opportunistic testing of BRCA1 , BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels
- (2019) Lídia Feliubadaló et al. INTERNATIONAL JOURNAL OF CANCER
- Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
- (2019) Bernadette A. M. Heemskerk-Gerritsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer
- (2019) Marcia Irene Canto et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
- (2019) Kala Visvanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on Genetic Testing in Gynecologic Cancer
- (2019) Susan M. Domchek et al. JOURNAL OF CLINICAL ONCOLOGY
- When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
- (2019) Kim DeLeonardis et al. Journal of Oncology Practice
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- BRCA1/2 testing: therapeutic implications for breast cancer management
- (2018) Nadine M. Tung et al. BRITISH JOURNAL OF CANCER
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review
- (2018) Ye-Lei Xiao et al. Clinical Breast Cancer
- Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
- (2018) Peter D. Beitsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risks of first and subsequent cancers amongTP53mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort
- (2016) Phuong L. Mai et al. CANCER
- Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
- (2016) X. Li et al. CLINICAL CANCER RESEARCH
- Counselling framework for moderate-penetrance cancer-susceptibility mutations
- (2016) Nadine Tung et al. Nature Reviews Clinical Oncology
- Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian
- (2014) Jacqueline Mersch et al. CANCER
- Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2013) Kelly-Anne Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- Familial breast cancer: summary of updated NICE guidance
- (2013) D. G. Evans et al. BMJ-British Medical Journal
- Clinical significance of large rearrangements inBRCA1andBRCA2
- (2012) Thaddeus Judkins et al. CANCER
- Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
- (2012) M.-H. Tan et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More